Silo Pharma, Inc. - Common Stock (NQ:SILO)

1.458 -0.002 (-0.14%)

Delayed Quote Updated: 3:59 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Silo Pharma, Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Fibromyalgia Care Breakthrough: DEA Green Lights Biotech Partnership Exploring Ketamine Implant Therapy ↗

December 28, 2023

Silo Pharma’s (NASDAQ: SILO) novel ketamine-loaded implant targeting fibromyalgia and chronic pain conditions, SP-26, is reportedly ad

Via Benzinga

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Regulatory Approval for Ketamine Implant, Moves Forward with Partner to Next Stage of Development

December 28, 2023

Via Investor Brand Network

Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia

December 28, 2023

From Silo Pharma, Inc.

Via GlobeNewswire

Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More ↗

December 27, 2023

President Biden Approves Psychedelics Clinical Trials For Active Military Members President Biden signed into law the 2024 National Defense Authorization Act (NDAA), large-scale legislation that also...

Via Benzinga

Psyched: Biden's Big Decision On Psychedelics Therapy; LSD Anxiety Results; Matthew Perry Autopsy And More ↗

December 18, 2023

Biden To Decide On Psychedelic Therapy Bill

Via Benzinga

Psyched: John Lennon Remembered, Clinical Trials For Service Members, Chrissy Teigen, Jon Feliciano And More ↗

December 11, 2023

John Lennon Remembered 43 Years After His Murder In New York, Psychedelic Adventures & Enduring Legacy

Via Benzinga

SHF Holdings And 3 Other Stocks Under $2 Insiders Are Buying ↗

December 08, 2023

The Dow Jones closed higher by over 60 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Topics Stocks

Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More ↗

December 05, 2023

Defense Dept. Funds Ketamine Study For PTSD Treatment

Via Benzinga

Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More ↗

November 24, 2023

GOP Candidate Vivek Ramaswamy Wants Legal Psychedelics And Cannabis For PTSD In New Veterans Plan

Via Benzinga

Topics Cannabis

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

November 23, 2023

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 22, 2023

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

November 21, 2023

Via Benzinga

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Inks Exclusive License Agreement with Medspray Pharma BV

November 21, 2023

Via Investor Brand Network

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 21, 2023

Via Benzinga

Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD

November 21, 2023

From Silo Pharma, Inc.

Via GlobeNewswire

Silo Pharma Collaborates With Medspray Pharma For Intranasal Technology For Stress Disorder Candidate ↗

November 21, 2023

Silo Pharma Inc (NASDAQ: SILO) announced a new exclusive license agreement with Medspray Pharma BV for its proprietary patented soft mist nasal spray technology, the delivery mechanism selected for...

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

November 17, 2023

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

November 17, 2023

It's time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!

Via InvestorPlace

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 15, 2023

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

November 15, 2023

It's time to dive into the biggest pre-market stock movers as we check out all of the hottest news worth reading about on Wednesday!

Via InvestorPlace

Psyched: Veterans & Psychedelics, $100M IPO, Cybin's $64M Offering, Worldwide Events & More ↗

November 12, 2023

Veterans Day: Can Psychedelic Treatment Help Stem PTSD-Related Suicides Among Veterans?

Via Benzinga

Topics Initial Public Offering

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) to Initiate Dose-Ranging Study, Positioning for Early Start of Phase 1 Clinical Trial of SPC-15

November 08, 2023

Via Investor Brand Network

Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD

November 08, 2023

Study to determine therapeutic relevant dose range and pharmacokinetic to be used for first-in-human trial

From Silo Pharma, Inc.

Via GlobeNewswire

Psyched: DEA's Denial Overruled, Fed Psychedelics Change, Psilocybin For Depression, States Reform & More ↗

November 06, 2023

DEA Psilocybin Rescheduling Denial Overruled By Federal Appeals Court

Via Benzinga

Topics Economy

Psyched: Cybin's Center Stage In Novel Psychedelics, Musk & Ramaswamy, Britney's Memoirs And More ↗

October 29, 2023

Cybin Officially Owns Small Pharma, Gets Three New International Patents Granted

Via Benzinga

Topics Intellectual Property

Psyched: Jada Pinkett-Smith's Ayahuasca Journey, RIP Dr. Roland Griffiths, Congressional VA Hearings Halted ↗

October 22, 2023

Jada Pinkett Smith Opens Up About Ayahuasca: It Helped Her Overcome Depression And Suicidal Thoughts

Via Benzinga

Psyched: FDA Warning, DEA's Telehealth Extension, CA Gov's Veto, Congress On Kratom, M&As & More ↗

October 16, 2023

Cybin And Small Pharma Shareholders Green Light Acquisition Resolution

Via Benzinga

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Positive Results of Preclinical Study to Advance SPU-21

October 16, 2023

Via Investor Brand Network

Silo Pharma’s SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis

October 16, 2023

From Silo Pharma, Inc.

Via GlobeNewswire

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Initiates Human Factor Study of Its Targeted Prophylactic Treatment SPC-15

October 11, 2023

Via Investor Brand Network

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.